Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Brain Neoplasms × Afatinib × Clear all

Phase

Status

Unknown 1 Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 7 Esophageal Squamous Cell Carcinoma 3 Pancreatic Neoplasms 2 NSCLC 2 Carcinoma, Squamous Cell 2 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Pathologic Complete Response 1 PFS 1 Neoplasms 1 NRG1-fused Non-small Cell Lung Cancer 1 Gastrointestinal Neoplasms 1 Focus of Study Instead 1 EGFR Mutation Positive Non-small Cell Lung Cancer 1 Colorectal Neoplasms 1 Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

Radiosurgery 12 Temozolomide 10 Radiotherapy 10 Magnetic Resonance Spectroscopy 7 Erlotinib Hydrochloride 6 Bevacizumab 6 Surgical Procedures, Operative 5 Pemetrexed 5 Drug Therapy 5 Carboplatin 5 pyrotinib 4 icotinib 4 aumolertinib 4 Gefitinib 4 Trastuzumab 3 Spermine Synthase 3 Radiation 3 Lomustine 3 Etoposide 3 Dexmedetomidine 3 Chlorotoxin 3 Carmustine 3 osimertinib 2 camrelizumab 2 apatinib 2 Tyrosine Kinase Inhibitors 2 Thiotepa 2 Surveys and Questionnaires 2 Sevoflurane 2 Propofol 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04158947 2020-05-12

HER2BAT

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Unknown

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡